Article

The Chinese-German Journal of Clinical Oncology

, 8:585

First online:

Expression profile of CD10, Bcl-6, CD138, Bcl-2 and MUM1 and their prognostic value in 136 patients with diffuse large B-cell lymphoma

  • Yan SongAffiliated withDepartment of Pathology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC)
  • , Zhi CaoAffiliated withDepartment of Pathology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC)
  • , Qin SuAffiliated withDepartment of Pathology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC)
  • , Ling LiAffiliated withDepartment of Pathology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC)
  • , Hongtu ZhangAffiliated withDepartment of Pathology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC)
  • , Yuankai ShiAffiliated withDepartment of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC)
  • , Xun ZhangAffiliated withDepartment of Pathology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC) Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Objective

We evaluated the value of using a panel of GC B-cell (CD10 and Bcl-6) and activation (MUM1, CD138 and Bcl-2) markers by immunohistochemistry to define prognosis in patients with diffuse large B-cell lymphoma (DLBCL).

Methods

Two different models (Hans’ and modified Chang’s model) were applied on 136 de novo DLBCL patients. Median follow-up in all patients was 39 months (range 5–80 months).

Results

According to Hans’ model, patients with GCB had much better overall survival (5-year OS, 75%) than those with non-GCB (5-year OS, 52%) (Kaplan-Meier survival analysis, P < 0.05, log rank test). According to modified Chang’s model, patients with group 1 had much better overall survival (5-year OS, 78%) than those with group 3 (5-year OS, 44%) while group 2 had no significant value compared with group 1 and group 3 in prognosis (Kaplan-Meier survival analysis, P < 0.05, log-rank test). Using multivariate Cox proportional hazards regression analysis, the international prognostic index scores (IPI), expression of CD138 and the expression pattern of modified Chang’s model were independent prognostic indicators.

Conclusion

Our results suggest that the expression patterns of the panel of GCB-cell and activation markers by immunohistochemistry correlate with prognosis of patients with DLBCL and both models can be used well in ordinary work.

Key words

diffuse large B-cell lymphoma GC B-cell activated B-cell prognosis